PRAX vs KYMR
Side-by-side comparison of price performance, valuation, growth, profitability, analyst targets and technical trend.
PRAX · Praxis Precision Medicines$300.43 ▼ 3.37%
KYMR · Kymera Therapeutics$115.31 ▼ 3.42%
One year, rebased to 100
Each line starts at 100 so growth is directly comparable
- PRAX +57.4%
- KYMR +75.8%
Head to head
| Metric | PRAX | KYMR |
|---|---|---|
| Price | $300.43 | $115.31 |
| Change today | ▼ 3.37% | ▼ 3.42% |
| Market cap | $8.40B | $9.84B |
| Return, 3 months | -18.4% | -4.7% |
| Return, year to date | +1.9% | +48.2% |
| Return, 1 year | +76.9% | +74.6% |
| P/E (TTM) | – | – |
| P/B | 6.7 | 6.1 |
| P/E percentile vs own 5y | 3rd | 3rd |
| Dividend yield | – | – |
| Revenue growth (YoY, latest qtr) | – | -100.0% |
| Net profit growth (YoY) | -27.5% | -60.6% |
| Gross margin | – | – |
| Operating margin | – | -396.0% |
| Net margin | – | -341.8% |
| Return on equity | -44.8% | -27.3% |
| Analyst target vs. price | +142.4% | +30.7% |
| Analyst buy share | 92% | 100% |
| RSI (14) | 51 | 41 |
| 30-day volatility | 80.1% | 51.7% |
| Max drawdown, 1 year | -38.1% | -27.7% |
| Trend read | Leaning bullish | Leaning bearish |
| Analyst consensus | Buy | Buy |
Green cells mark the best value in each row where "better" is clear-cut (lower P/E, higher margin). That is a reading of the numbers, not a recommendation. Financials are in each company's reporting currency.
What the numbers say
- KYMR is the largest of the group by market value.
- PRAX has returned the most over the past year.
- KYMR has been the calmest stock over the last 30 days.